Comparison · NCT02118792-1a52ca63
AN2728 Topical Ointment, 2 Percent (%) vs AN2728 Topical Ointment, Vehicle: Number of Participants With Clinically Significant Laboratory Values
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AN2728 Topical Ointment, 2 Percent (%) vs AN2728 Topical Ointment, Vehicle: Number of Participants With Clinically Significant Laboratory Values. Trial comparisons, record NCT02118792-1a52ca63. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02118792-1a52ca63
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00784 | 0.00305 | 0.02 | wilson | |
| Risk in group 2 | 0.0162 | 0.00632 | 0.0409 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00835 | -0.0335 | 0.00731 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.484 | 0.122 | 1.92 | log | |
| Odds ratio, group 1 over group 2 | 0.48 | 0.119 | 1.94 | log | |
| Number needed to treat, for one fewer participant with the outcome on AN2728 Topical Ointment, 2 Percent (%) than on AN2728 Topical Ointment, Vehicle | 120 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AN2728 Topical Ointment, 2 Percent (%) | AN2728 ointment, 2% was applied topically twice daily, to all treatable AD-involved areas (excluding scalp), from Day 1 up to Day 28 in each participant. Treatable AD-involved areas were identified at Baseline (Day 1) by investigator. | 4 | 510 | OG000 |
| Group 2 | AN2728 Topical Ointment, Vehicle | AN2728 ointment, vehicle was applied topically twice daily, to all treatable AD-involved areas (excluding scalp), from Day 1 up to Day 28 in each participant. Treatable AD-involved areas were identified at Baseline (Day 1) by investigator. | 4 | 247 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Clinically Significant Laboratory Values
- Description
Laboratory values included: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Albumin, Bilirubin, Blood Urea Nitrogen, Glucose, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets, Basophils, Eosinophils, Erythrocytes, Potassium, Protein, Sodium. Clinically significant laboratory abnormalities were defined as abnormal laboratory test values that have clinical manifestations or require medical intervention, as per investigator's discretion.
- Time frame
- Baseline up to Day 36
- Population
- Safety population included all randomized participants who had at least 1 confirmed dose of study drug, and had at least 1 post-baseline assessment.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
- NCT number
- NCT02118792
- Phases
- PHASE3
- Conditions
- Dermatitis, Atopic
- Interventions
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Lead sponsor
- Pfizer
- Results first posted
- 2017-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02118792?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02118792-1a52ca63